Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02385266 · ClinicalTrials.gov registry record · Phase 4

Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain

A Phase 4 study, sponsored by Northwestern University.

Terminated
Registry status
Phase 4
Development phase
24
Enrollment target

NCT02385266: Clinical Trial Phase 4 study, sponsored by Northwestern University.

NCT02385266 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02385266, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.

TERMINATED
Registry status
Phase 4
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the efficacy of D-Cycloserine versus placebo treatment in reducing pain from urological chronic pelvic pain syndrome (UCPPS).

Primary Outcome

The visual analog scale (VAS) is a measurement tool used to assess the level of pain experienced by a patient. The scale is a 100 mm horizontal line, with one end representing "no pain" and the other end representing "worst pain imaginable." The patient is asked to mark on the line the point that best represents their level of pain. The minimum score is 0 mm, indicating no pain, while the maximum score is 100 mm, indicating the worst pain imaginable. Higher scores on the VAS indicate a worse ou

Interventions

  • DRUG D-Cycloserine
  • DRUG Placebo (for D-cycloserine)

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2013-09
Est. Completion 2016-06
Phase Phase 4
Northwestern University

1,209 total trials

Why NCT02385266 stopped before completion

NCT02385266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which D-Cycloserine is the first listed.

NCT02385266 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02385266 about?

NCT02385266 is a clinical study titled "Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain". The purpose of this study is to evaluate the efficacy of D-Cycloserine versus placebo treatment in reducing pain from urological chronic pelvic pain syndrome (UCPPS).

What is the current status of trial NCT02385266?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2013-09. Estimated completion is 2016-06.

What interventions are being tested in trial NCT02385266?

The interventions under investigation include: D-Cycloserine (DRUG), Placebo (for D-cycloserine) (DRUG).

Who is sponsoring clinical trial NCT02385266?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02385266's enrollment target sits among peer trials

24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02385266, the US trial registry maintained by the National Library of Medicine. NCT02385266 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.